Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Treasury Shares (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Treasury Shares for 9 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares rose 3.53% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Dec 2025, up 3.53%, and an annual FY2025 reading of $1.3 million, up 3.53% over the prior year.
  • Treasury Shares was $1.3 million for Q4 2025 at Puma Biotechnology, down from $1.4 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.5 million in Q1 2021 and bottomed at $1.3 million in Q4 2024.
  • Average Treasury Shares over 5 years is $1.8 million, with a median of $1.8 million recorded in 2025.
  • The sharpest move saw Treasury Shares fell 24.53% in 2021, then grew 24.33% in 2023.
  • Year by year, Treasury Shares stood at $1.4 million in 2021, then grew by 7.32% to $1.5 million in 2022, then rose by 8.2% to $1.6 million in 2023, then decreased by 20.65% to $1.3 million in 2024, then increased by 3.53% to $1.3 million in 2025.
  • Business Quant data shows Treasury Shares for PBYI at $1.3 million in Q4 2025, $1.4 million in Q3 2025, and $1.8 million in Q2 2025.